Article Text

Download PDFPDF
Case report
Rapidly recurring ovarian fibrosarcoma after optimal debulking surgery in a 46-year-old woman
  1. Hariyono Winarto1,2,
  2. Tantri Hellyanti2,3,
  3. Sigit Purbadi1,2 and
  4. Sutrisno Sutrisno1,2
  1. 1Department of Obstetrics and Gynaecology, Dr Cipto Mangunkusumo Hospital, Central Jakarta, Indonesia
  2. 2Faculty of Medicine, Universitas Indonesia, Central Jakarta, Indonesia
  3. 3Department of Anatomical Pathology, Dr Cipto Mangunkusumo Hospital, Central Jakarta, Indonesia
  1. Correspondence to Dr Hariyono Winarto; hariyono.winarto{at}ui.ac.id

Abstract

Ovarian fibrosarcoma is an extremely rare tumour with no universally accepted guidelines for treatment. We present a 46-year-old nulliparous woman with ovarian fibrosarcoma who mainly presented with a painful abdominal enlargement. Optimal debulking surgery was performed, and a specimen of the tumour was examined. A frozen section examined during surgery revealed spindle cell morphology, raising the suspicion of ovarian fibrosarcoma, which was later confirmed by immunohistochemistry staining. Our patient refused to undergo chemotherapy and died 3 months after surgery due to tumour recurrence. Although no clear consensus exists for administering chemotherapy for fibrosarcoma, some published case reports have shown a lower chance of recurrence and better prognosis in patients who undergo chemotherapy compared with our patient.

  • oncology
  • gynecological cancer
  • surgical oncology

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors HW and TH: concept. HW, TH, SP and SS: data collection or processing. HW and SS: literature search. HW: writing.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Next of kin consent obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.